Emory researchers' single-site PMA for LASIK excimer system slated for panel review July 11.
This article was originally published in The Gray Sheet
Executive Summary
EMORY UNIV. PHYSICIANS' SINGLE-SITE LASIK PMA TO GET PANEL REVIEW July 11 by FDA's Ophthalmic Devices Panel at the Gaithersburg Hilton in Maryland. The physician-sponsored premarket approval application covers use of a modified Summit Omnimed excimer laser for treating myopia of -2.0 to -22.0 diopters via the laser in situ keratomileusis procedure. The PMA is being sponsored by Atlanta-based Vision Correction Group, Inc., which is comprised of physicians practicing at the Emory University Vision Correction Center.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.